OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.530
-0.050 (-3.16%)
May 30, 2025, 4:00 PM - Market closed

OS Therapies Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cost of Revenue
---01.164.25
Gross Profit
----0-1.16-4.25
Selling, General & Admin
7.43.971.131.151.50.8
Research & Development
3.792.843.223.292.170.6
Operating Expenses
11.186.814.344.453.681.4
Operating Income
-11.18-6.81-4.34-4.45-4.84-5.65
Interest Expense
-1.22-2.05-3.45-1.81-2.58-0.46
Interest & Investment Income
0-0--0.06
Other Non Operating Income (Expenses)
1.11-0.02---0.02
Pretax Income
-11.3-8.88-7.79-6.25-7.42-6.03
Net Income
-11.3-8.88-7.79-6.25-7.42-6.03
Preferred Dividends & Other Adjustments
1.9720.130.130.09-
Net Income to Common
-13.27-10.89-7.92-6.38-7.51-6.03
Shares Outstanding (Basic)
1612510108
Shares Outstanding (Diluted)
1612510108
Shares Change (YoY)
270.21%127.97%-45.60%-18.50%-
EPS (Basic)
-0.82-0.88-1.46-0.64-0.75-0.72
EPS (Diluted)
-0.82-0.88-1.46-0.64-0.75-0.72
Free Cash Flow
-10.08-7.28-3.01-3.79-4.41-2.42
Free Cash Flow Per Share
-0.62-0.59-0.55-0.38-0.44-0.29
EBITDA
-11.18-6.81-4.34-4.45-4.84-5.65
D&A For EBITDA
000000
EBIT
-11.18-6.81-4.34-4.45-4.84-5.65
Updated May 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q